

18 March 2022

## Migrane Pharma

How many patients have been treated with the following drugs in the past 4 months:

- Erenumab (Aimovig) - any disease 0
- Fremanezumab (Ajovy) - any disease 0
- Galcanezumab (Emgality) - any disease 0
- **Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY.** The information requested is not collated centrally and an extensive trawl of patient notes would be required. We estimate that compliance with this request for information would exceed the appropriate costs limit. Under Section 12 of the Freedom of Information 2000, the limit has been specified as £450 and represents the estimated cost of one or more persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information.

**B.I would like to understand the source of funding of Botox and anti-CGRP monoclonal antibody treatments (Ajovy, Aimovig, Emgality) for migraine.**

**Could you please answer the following questions:**

- **Does the trust commission/fund Botulinum Toxin treatment for migraine (Y/N)?** Yes
- **Does the trust commission/fund anti-CGRP treatments for migraine (Y/N)?** Currently the Trust is looking at this being commissioned.
- **In case the trust actively provides Botulinum Toxin treatment for migraine but does not commission/fund it, then please provide the name(s) of the other NHS organisations that commission/fund these treatments at your trust.**
- **In case the trust actively provides anti-CGRP treatments for migraine but does not commission/fund them, then please provide the name(s) of the other NHS organisations that commission/fund these treatments at your trust.** Southern Trust and South Eastern Trust.